New antibody drug aims to outsmart tumors by targeting two immune pathways

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily sign the informed consent form, understand the study, are willing to comply with and have the ability to complete all trial procedures; * Age 18-75 years (inclusive), any gender; * Have histologically or cytologically confirmed locally advanced or metastatic solid tumors, and have failed standard therapy, or are intolerant to standard therapy, or for whom standard therapy is not available; * Able to provide tumor tissue specimens and peripheral blood samples that meet testing requirements, or provide prior test reports that meet the requirements; * ECOG performance status of 0 or 1; * Expected survival ≥3 months; * Have at least one measurable tumor lesion according to RECIST 1.1 criteria; * Adequate cardiac, bone marrow, liver, renal function; Exclusion Criteria: * Have received a live vaccine within 3 months prior to randomization; * Have received radiotherapy within 4 weeks prior to randomization; * Have received other anti-tumor drug therapy within 4 weeks or within 5 half-lives of the anti-tumor drug prior to randomization; * Have undergone major surgery within 4 weeks prior to randomization; * Have received any clinical study drug treatment within 4 weeks prior to randomization; * Have undergone major surgery within 4 weeks prior to randomization; * Have a history of other (non-study tumor) malignancies within 3 years prior to randomization; * Have received any organ transplant or bone marrow transplant; * Have previously received any tumor necrosis factor receptor (TNFR) agonist antibody therapy, such as anti-CD40, anti-OX40, anti-CD137, anti-CD27, anti-CD357 antibodies, etc; * Have experienced Grade ≥3 immune-related adverse events (irAEs) from prior immunotherapy; * Have a history of severe allergic reactions or are allergic to the investigational drug (FG-B901); * Have a history of central nervous system metastases and/or carcinomatous meningitis; * Have adverse reactions from prior treatments that have not recovered to CTCAE v5.0 Grade ≤1 (excluding alopecia and anemia) prior to randomization; * Have a history of severe respiratory disease; * Have experienced a clinically significant cardiac disease within 6 months before the first dose of study drug; * Have uncontrolled systemic diseases assessed by the investigator, including diabetes, hypertension, pulmonary fibrosis, interstitial lung disease, etc.; * The investigator judges the subject to have obvious active gastrointestinal bleeding; * Known history of Hepatitis C or chronic active Hepatitis B; * Have experienced systemic treatment with corticosteroids within ≤2 weeks prior to randomization; * Any other condition of the subject (e.g., psychological, geographical, or medical condition) that does not permit compliance with the study and follow-up procedures; * Are pregnant or breastfeeding;